camsol
solpro
analysi
secondari
structur
element
alpha
helix
extend
strand
random
coil
perform
use
psipr
tool
tertiari
structur
analysi
carri
use
tool
modrefin
procheck
biolog
function
allergen
evalu
base
tool
deepgoplu
allergenfp
correspondingli
best
dock
complex
term
lowest
dock
energi
pv
receptor
chosen
immun
simul
studi
use
cimmsim
tool
along
two
posit
vaccin
control
mention
section
one
neg
vaccin
control
compar
simul
result
design
use
suitabl
linker
well
nonbind
hla
class
ii
epitop
appli
strategi
use
pv
nonepitop
molecular
dock
antibodi
pdb
id
well
pdb
id
pv
perform
use
cluspro
tool
along
cocrystal
respect
control
epitop
npdpnanpnvd
iedb
id
nanpnanpnanpnanpnanp
iedb
id
pf
csp
molecular
dynam
top
dock
complex
perform
imod
server
explain
collect
protein
motion
intern
coordin
normal
mode
analysi
nma
nma
dihedr
coordin
natur
mimic
combin
function
motion
protein
molecul
model
set
atom
connect
harmon
spring
j
u
r
n
l
p
r
e
p
r
f
dna
code
sequenc
oral
pv
optim
elev
protein
express
use
java
codon
adapt
tool
jcat
follow
option
select
lactococcu
lacti
strain
express
host
ii
avoid
rhoindepend
transcript
termin
iii
avoid
prokaryot
ribosom
bind
site
iv
avoid
cleavag
site
restrict
enzym
silico
clone
cdna
stop
codon
snapgen
softwar
use
involv
insert
restrict
site
fspi
plasmid
vector
gene
bank
access
number
accord
violin
databas
access
june
total
vaccin
avail
far
p
falciparum
differ
lifecycl
stage
succeed
get
approv
fda
usa
worldwid
market
rt
world
first
european
medicin
agenc
ema
approv
malaria
vaccin
partial
protect
young
children
use
subsaharan
african
region
along
sever
advers
effect
incur
advers
effect
addit
efficaci
declin
almost
zero
th
year
neg
th
year
aforement
fact
warrant
exhaust
effortsresearch
toward
develop
effect
pv
elicit
robust
immun
respons
global
present
studi
extens
previou
report
exploit
homolog
antigen
conserv
among
human
malaria
parasit
p
falciparum
p
vivax
p
oval
p
malaria
minimum
ident
recogn
blastp
tool
potenti
platform
design
pv
recent
year
epitop
base
design
vaccin
new
strategi
employ
worldwid
research
toward
develop
effici
pv
numer
diseas
leishmaniasi
malaria
context
exploit
comput
approach
costeffect
vaccin
develop
also
diminish
time
period
risk
failur
experiment
studi
studi
continu
b
cell
epitop
forecast
gdpap
use
bcpred
supplementari
tabl
continu
b
cell
epitop
found
possess
total
tcell
epitop
includ
hla
class
epitop
hla
class
ii
epitop
supplementari
tabl
tcell
epitop
forecast
pool
predict
continu
bcell
epitop
antigen
present
tcell
suppos
j
u
r
n
l
p
r
e
p
r
f
effici
recogn
bcell
addit
antigenspecif
bcell
may
present
multipl
tcell
epitop
immun
system
thu
enhanc
abil
trigger
specif
manner
base
ppc
analysi
epitop
ensembl
hla
class
epitop
hla
class
ii
epitop
world
coverag
design
use
criteria
describ
previous
tabl
howev
combin
set
also
report
similar
studi
conduct
pritam
et
al
case
malaria
adapt
immun
system
elicit
cellular
humor
immun
respons
associ
b
lymphocyt
respect
howev
mainli
lymphocyt
also
known
helper
cell
th
elicit
correspondingli
regul
malaria
infect
besid
tlr
also
involv
activ
differ
signal
cascad
ultim
express
gene
proinflammatori
cytokin
like
etc
associ
deplet
liverstag
parasit
also
support
present
studi
epitop
found
induc
respons
correspondingli
supplementari
tabl
amongst
aforement
epitop
ensembl
record
one
potent
candid
induc
respons
found
suppress
pathogen
inflammatori
respons
concern
control
malaria
parasit
linear
bcell
epitop
link
antibodi
gener
identif
epitop
use
tradit
approach
costli
also
time
consum
involv
difficult
process
order
overcom
aforement
issu
present
studi
involv
predict
tcell
epitop
use
linear
bcell
epitop
input
instead
whole
antigen
minim
size
pv
also
elicit
cellular
cell
epitop
well
humor
bcell
epitop
immun
respons
non
toxic
natur
adjuv
b
also
help
product
sever
cytokin
eg
induct
dendrit
cell
b
cell
macrophag
tcell
ultim
boost
concentr
antibodi
report
sever
studi
link
variou
diseas
caus
agent
includ
human
rotaviru
hiv
helicobact
pylori
influenza
viru
therefor
pv
design
epitop
ensembl
cell
epitop
andor
linear
bcell
epitop
epitop
ensembl
differ
linker
well
adjuv
respons
activ
receptor
pertain
malaria
initi
five
nonadjuv
pv
design
follow
incorpor
bind
specif
adjuv
result
respect
design
adjuv
pv
ie
tabl
eaaak
linker
incorpor
ntermin
pv
stiff
prevent
assembl
adjuv
vaccin
domain
although
adjuv
found
enhanc
immunogen
vaccin
may
caus
toxicityadvers
reaction
therefor
design
pv
without
adjuv
design
cell
epitop
hla
j
u
r
n
l
p
r
e
p
r
f
class
ii
join
togeth
use
linker
l
l
likewis
exploit
mere
linear
bcell
epitop
attach
togeth
linker
l
similarli
tand
bcell
epitop
join
linker
l
l
exploit
mere
linear
bcell
epitop
attach
togeth
linker
l
amongst
two
linker
l
univers
linker
enhanc
proteasom
process
along
immunogen
l
flexibl
linker
stimul
better
immun
respons
exemplari
vaccin
found
induc
multiimmun
respons
band
tcell
immun
respons
therefor
design
pv
tand
bcell
epitop
use
elicit
humoralcellular
respons
differ
respect
linker
l
l
respect
use
join
continu
bcell
epitop
howev
case
design
neg
polypeptid
vaccin
control
linker
employ
connect
nonhla
class
ii
cell
epitop
tabl
b
tcell
epitop
bcell
epitop
tlr
especi
surfac
one
viz
well
avail
immun
cell
also
epitheli
cell
fibroblast
recogn
pamp
bridg
innat
well
adapt
immun
host
regul
balanc
ribosom
design
pv
could
good
choic
p
falciparum
even
combin
two
distinct
tlr
agonist
adjuv
subunit
vaccin
show
synerget
protect
efficaci
altogeth
fact
led
hypothesi
use
receptor
agonist
b
respect
design
pv
subsequ
dock
experi
perform
reveal
possibl
associ
among
pv
tlr
molecular
dock
tertiari
structur
pv
predict
reveal
amino
acid
favour
region
overal
dock
studi
carri
use
tool
includ
control
receptor
respect
tabl
result
total
dock
model
ie
includ
pv
control
quit
interest
note
pv
design
without
adjuv
also
abl
interact
dock
good
energi
score
control
except
therefor
might
capabl
elicit
innat
immun
well
agreement
earlier
studi
regard
rapid
product
amongst
design
pv
abl
dock
cluspro
tool
respect
receptor
total
potenti
pv
dock
model
obtain
dock
energi
control
model
kcalmol
kcalmol
complex
found
higher
design
potenti
pv
indic
dock
pv
form
stronger
immunolog
complex
control
ligand
amongst
design
pv
without
adjuv
show
lowest
dock
energi
kcalmol
kcalmol
respect
receptor
correspondingli
clearli
indic
pv
without
adjuv
interact
domain
induc
innat
immun
system
agreement
recent
studi
human
selfassembl
peptid
nanoparticl
use
non
toxic
vaccin
adjuv
filari
antigen
protein
induc
immunolog
respons
mice
besid
linker
util
design
tabl
howev
base
overal
dock
j
u
r
n
l
p
r
e
p
r
f
score
receptor
respect
select
lead
pv
structur
function
analysi
fig
forecast
allergenfp
tool
threshold
valu
also
secondari
structur
analysi
ssa
protein
benefici
understand
fold
stabil
well
function
context
present
studi
reveal
alpha
helic
tabl
lead
pv
also
predict
involv
multiorgan
process
well
cell
adhes
immun
system
process
respect
predict
deepgoplu
tool
base
deep
convolut
neural
network
model
gene
ontolog
go
scheme
overal
structur
function
analysi
lead
pv
show
compar
similar
properti
posit
vaccin
control
tabl
thu
lead
polypeptid
vaccin
capabl
j
u
r
n
l
p
r
e
p
r
f
induc
humor
well
cellular
immun
respons
howev
oral
administ
polypeptid
vaccin
suffer
poor
stabil
insolubl
weak
bioavail
low
immunogen
due
acid
environ
upper
gitract
ineffici
deliveri
mucosaassoci
lymphoid
tissu
therefor
genet
engin
l
lacti
express
host
use
product
deliveri
vaccin
antigen
due
sever
advantag
properti
viz
easi
safe
product
well
storag
surviv
gastric
environ
selfadjuvant
multiorgan
process
immun
system
process
cell
adhes
cours
human
malaria
infect
proinflammatori
antiinflammatori
cytokin
produc
cell
respect
addit
cytotox
lymphocyt
natur
killer
cell
macrophag
activ
elicit
help
control
pathogen
effect
even
success
vaccin
candid
malaria
rt
report
elicit
igg
titer
activ
cell
respons
background
present
studi
involv
immun
simul
use
cimmsim
tool
along
posit
vaccin
control
tabl
selfassembl
polypeptid
nanoparticl
sapn
base
p
falciparum
antigen
interact
antibodi
induc
humor
immun
respons
help
clearanc
pathogen
igg
antibodi
name
order
decreas
abund
one
abund
pathogen
neutral
molecul
found
human
serum
antibodi
share
amino
acid
sequenc
ident
subclass
exclus
effector
properti
includ
halflif
epitop
bind
immunolog
complex
format
complement
activ
trigger
effector
cell
placent
transport
moreov
igg
profil
given
individu
determin
inherit
allotyp
potenti
influenc
clinic
manifest
immun
respons
howev
broadli
neutral
j
u
r
n
l
p
r
e
p
r
f
antibodi
bnab
found
rare
popul
patient
control
infect
bnab
tend
target
differ
conserv
antigen
region
expos
outer
surfac
pathogen
across
circul
strain
present
studi
proteinprotein
global
dock
method
cluspro
server
use
reveal
shape
complementar
pv
ligand
interact
domain
antibodi
receptor
elimin
need
long
term
exposur
malaria
patient
select
antigen
mimet
involv
epitop
pfalciparum
strain
antibodi
could
consid
bnab
found
well
detect
neutral
activ
wet
lab
experiment
studi
furthermor
respect
sourc
protein
epitop
character
lead
vaccin
candid
also
antibodi
found
associ
human
malaria
protect
thu
structur
base
vaccinolog
approach
could
exploit
predict
probabl
potent
pv
might
abl
block
infect
even
effect
data
lead
provok
molecular
interact
studi
lead
pv
well
along
cocrystal
control
epitop
toward
antibodi
tabl
fig
j
u
r
n
l
p
r
e
p
r
f
molecular
dynam
studi
crucial
evalu
stabil
proteinprotein
complex
determin
compar
necessari
protein
dynam
normal
mode
nma
allow
demonstr
dock
proteinprotein
complex
mobil
stabil
sequenc
length
obtain
cdna
bp
bp
correspondingli
codon
adapt
index
cai
valu
respect
reliabl
optim
codon
cai
valu
lie
howev
gc
content
improv
dna
sequenc
found
lie
optim
rang
could
easili
express
suitabl
express
host
although
p
falciparum
antigen
could
express
e
coli
requir
codon
harmon
reduct
amino
acid
j
u
r
n
l
p
r
e
p
r
f
misincorpor
improv
immunogen
present
studi
solubilis
probabl
recombin
protein
express
e
coli
reveal
bioinformat
tool
rpsp
proteinsol
camsol
solpro
lower
compar
posit
vaccin
control
indic
look
altern
express
host
tabl
addit
l
lacti
use
express
host
altern
e
coli
due
follow
advantag
properti
gener
recogn
safe
gra
microorgan
ii
lack
outer
membran
iii
insignific
extracellular
proteolysi
activ
iv
free
endotoxin
v
lipopolysaccharid
contamin
vii
accommod
cysteinerich
protein
vii
access
induc
constitut
genet
control
system
viii
abl
express
pronetoaggreg
andor
difficulttopurifi
protein
ix
present
host
immun
system
context
microparticl
avoid
immunotoler
normal
provok
oral
deliveri
solubl
antigen
x
exhibit
similar
codon
bia
p
falciparum
make
effici
protein
express
secret
system
outer
surfac
could
easili
interact
host
immun
system
recent
year
sever
wet
lab
studi
confirm
util
l
lacti
express
host
produc
properli
fold
pure
stabl
chimer
singl
antigen
protein
mani
pathogen
elicit
high
level
function
antibodiescytokin
includ
p
moreov
l
lactismedi
deliveri
dna
vaccin
also
lead
express
posttransl
modifi
antigen
host
cell
result
present
conform
restrict
epitop
immun
system
induct
cellular
humor
immun
respons
also
aforement
properti
last
two
decad
wit
use
genet
engin
l
lacti
system
effect
oral
base
vaccin
vehicl
deliv
antigen
virus
bacteria
parasit
elicit
system
mucos
immun
final
size
recombin
dna
obtain
insert
cdna
express
vector
observ
bp
bp
respect
lie
insid
orf
could
translat
respect
protein
sequenc
four
addit
amino
acid
mckc
nterminu
fig
therefor
ideal
multiepitop
polypeptid
vaccin
compos
seri
epitop
adjuv
elicit
simultan
strong
innat
adapt
howev
present
problem
field
multiepitop
vaccin
design
includ
select
appropri
candid
antigen
systemat
arrang
immunodomin
epitop
effect
oral
deliveri
viruslik
particl
sapn
present
studi
success
util
immunoinformat
tool
predict
suitabl
epitop
ensembl
target
protein
design
multiepitop
malaria
oral
vaccin
surprisingli
far
licens
malaria
vaccin
avail
market
protect
worldwid
human
popul
regardless
decad
research
one
major
bottleneck
malaria
vaccin
develop
immun
escap
mechan
pathogen
antigen
variat
hla
divers
design
pv
present
studi
may
overcom
aforement
issu
possess
b
cell
epitop
deriv
antigen
protein
involv
multi
stage
pathogen
lifecycl
worldwid
human
popul
coverag
moreov
pv
higher
potenti
elicit
innat
adapt
cellular
humor
immun
respons
howev
warrant
experiment
valid
evalu
efficaci
preclin
studi
studi
selffinanc
receiv
grant
fund
agenc
b
deform
c
eigenvalu
e
f
varianc
map
g
h
correl
matrix
j
elast
network
model
k
l
colour
bar
show
individu
red
cumul
green
varianc
correl
matrix
elast
network
graph
dot
colour
accord
stiff
darker
grey
indic
stiffer
spring
vice
versa
n
